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Abstract
Genetic and biochemical abnormalities of a-synuclein are associated with the pathogenesis of Parkinson’s disease. In the
present study we investigated the in vivo interaction of mouse and human a-synuclein with the potent parkinsonian
neurotoxin, MPTP. We find that while lack of mouse a-synuclein in mice is associated with reduced vulnerability to MPTP,
increased levels of human a-synuclein expression is not associated with obvious changes in the vulnerability of
dopaminergic neurons to MPTP. However, expressing human a-synuclein variants (human wild type or A53T) in the a-
synuclein null mice completely restores the vulnerability of nigral dopaminergic neurons to MPTP. These results indicate
that human a-synuclein can functionally replace mouse a-synuclein in regard to vulnerability of dopaminergic neurons to
MPTP-toxicity. Significantly, a-synuclein null mice and wild type mice were equally sensitive to neurodegeneration induced
by 29NH2-MPTP, a MPTP analog that is selective for serotoninergic and noradrenergic neurons. These results suggest that
effects of a-synuclein on MPTP like compounds are selective for nigral dopaminergic neurons. Immunoblot analysis of b-
synuclein and Akt levels in the mice reveals selective increases in b-synuclein and phosphorylated Akt levels in ventral
midbrain, but not in other brain regions, of a-synuclein null mice, implicating the a-synuclein-level dependent regulation of
b-synuclein expression in modulation of MPTP-toxicity by a-synuclein. Together these findings provide new mechanistic
insights on the role a-synuclein in modulating neurodegenerative phenotypes by regulation of Akt-mediated cell survival
signaling in vivo.
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Introduction
Parkinson’s disease (PD) is predominantly an idiopathic disorder
without cure and with limited symptomatic treatment. PD is
marked by a selective and progressive loss of dopaminergic
neurons in the substantia nigra pars compacta (SNpc) character-
ized by movement abnormalities including resting tremor,
bradykinesia, postural instabiltity and rigidity[1]. Currently, both
environmental and genetic factors are implicated in the patho-
genesis of PD [2]. The genetic cause for PD was first established
with identification of mutations in the gene encoding for the
synaptic protein a-synuclein in several families with the autosomal
dominant form of PD [3,4,5,6]. A relationship between a-
synuclein and PD is further suggested by the finding that a-
synuclein is the main structural component of cytoplasmic
proteinaceous inclusion bodies (Lewy bodies) and neurites (Lewy
neurites) that are characteristic of both sporadic and familial PD
cases [7]. Further, transgenic drosophila overexpressing human a-
synuclein demonstrates selective dopaminergic neuronal dysfunc-
tion [8] and forced overexpression of human a-synuclein in
rodents show varying degrees of neuronal dysfunction and
degeneration [9,10,11,12,13] including dopaminergic degenera-
tion [14,15,16,17,18]. However, a variety of human a-synuclein
transgenic mice with increased a-synuclein aggregation, motoric
dysfunction, and neurodegeneration have failed to show overt
neurodegeneration of dopaminergic neurons [10,11,12]. Thus, the
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degeneration is unresolved.
In addition, the relationship of a-synuclein abnormalities to
other in vivo models of PD remains controversial. A widely used
animal model of parkinsonism utilizes the selective dopaminergic
neurotoxin MPTP that replicates the selective neuronal loss seen
in PD [19,20,21]. A potential role for a-synuclein abnormalities in
the pathogenesis of MPTP toxicity is suggested from the findings
that a-synuclein aggregation occurs in mouse and primate models
of MPTP-induced parkinsonism [21,22,23]. However, studies
using rodents with increased expression of human a-synuclein
have led to conflicting results where some studies show lack of
increased sensitivity to MPTP with human a-synuclein expression
[24,25] and some studies showing increased sensitivity/abnormal-
ity associated MPTP in human a-synuclein transgenic mice
[26,27]. The discordance between these studies may be associated
with number of factors including differences in MPTP toxicity
paradigm used, promoters used, mouse strains, and the age of
animals used for the MPTP treatment. Lack of more robust and
consistent increase in MPTP toxicity with the overexpression of
human a-synuclein is puzzling since several studies show that the
expression of endogenous mouse a-synuclein is required to
sensitize dopaminergic neurons to MPTP [21,28,29,30,31]. One
of the possibilities is that human a-synuclein does not function in
the MPTP toxicity pathway in rodents.
In this report, we have attempted to more fully document the in
vivo relationship between a-synuclein expression and vulnerability
of dopaminergic neurons to MPTP. We used multiple transgenic
lines at multiple conditions to confirm that increased expression of
human a-synuclein is not associated with robust increase in the
susceptibility of the human a-synuclein transgenic mice to MPTP
toxicity. However, human a-synuclein is able to restore the
MPTP-sensitivity of the dopaminergic neurons lacking mouse a-
synuclein expression, showing that human a-synuclein can
functionally replace mouse a-synuclein in regard to vulnerability
of dopaminergic neurons to MPTP-toxicity. Significantly, the
mouse a-synuclein null mice are not protected from neurodegen-
eration induced by 29NH2-MPTP, the MPTP analog with
selective toxicity to central noradrenergic and serotoninergic
neurons [32,33]. This indicates that the MPTP resistance
phenotype of mouse a-synuclein null mice is selective for
dopaminergic neurons and that alterations in the general
metabolism and/or trafficking of MPP+ in the synaptic terminal
are not involved in MPTP resistant phenotype of the mouse a-
synuclein null mice. We also find that the levels of b-synuclein and
phosphorylated Akt is inversely correlated with a-synuclein
expression in the nigro-striatal system and increased b-synuclein
and phosphorylated Akt (pAkt) levels correlate with the protection
from MPTP toxicity. Thus, we propose that regulation of b-
synuclein and Akt levels by a-synuclein expression is an important
contributor to regulation of MPTP-toxicity by a-synuclein.
Results
Increased expression of human a-synuclein does not
increase vulnerability of dopaminergic neurons to MPTP-
intoxication
Acute MPTP paradigm. Eleven to thirteen week old
transgenic mice generated using the mouse prion promoter,
overexpressing wild type (line I2-2) or mutant A53T (line N2-5) or
mutant A30P (line T3) human a-synuclein, and non transgenic
littermates received either an acute paradigm of MPTP (18 mg
MPTP/kg free base X4, every two hours) or saline. One week
following treatment, HPLC with electrochemical detection
demonstrates a profound reduction in total striatal dopamine
following an acute paradigm of MPTP-treated mice compared to
saline controls (Fig. 1A) (ANOVA, p,0.05). Analysis of striatal
levels of dopamine and its metabolite DOPAC showed no
differences in the losses between any of the transgenic lines and
non-transgenic cohorts following MPTP administration. MPTP
treatment also results in increased striatal dopamine turnover
(DOPAC/DA) which is not statistically different in any of the
transgenic lines compared to non-transgenic animals (data not
shown). Stereologic counts of total neurons (Nissl positive) and
TH-immunopositive neurons in substantia nigra show that MPTP
treatment results in a significant decrease in total and TH-
immunopositive neurons of the SNpc in all lines of mice (Fig. 1B)
(ANOVA, p,0.05). However, no differences in susceptibility to
MPTP are observed between transgenic versus non-transgenic
mice.
Sub- acute MPTP paradigm. It is suggested that the
paradigm of MPTP delivery may have an effect upon
mechanisms of neuronal death. Sub-acute MPTP paradigms
may cause apoptotic mechanisms of neuronal death [34,35,36] not
seen in acute paradigms, which causes necrotic cell death [37].
Thus, we treated eleven to thirteen weeks old transgenic mice,
expressing the A53T mutant human a-synuclein (line N2-5), and
non-transgenic litter mates with a 5 day sub-acute MPTP
paradigm (30 mg MPTP/kg free base once daily for five days).
Stereologic neuronal counts were performed 2 weeks following the
final MPTP dose (Fig. 2A). Although, a significant loss of total and
TH-immunopositive neurons were seen following MPTP
administration compared to saline controls (ANOVA, p,0.05),
no difference was seen among transgenic and non-transgenic lines.
Identical results were obtained with the A30P mutant human a-
synuclein transgenic mice treated with the sub-acute MPTP
paradigm (data not shown).
Effect of age on the susceptibility of dopaminergic
neurons to MPTP. Because aging is associated with increased
vulnerability to MPTP-intoxication [38,39] and increased
vulnerability to a-synuclein dependent neurodegeneration [11],
we examined if age had a synergistic effect with over expression of
mutant human a-synuclein on the susceptibility to nigral
dopaminergic neurons following MPTP-intoxication. Transgenic
and non-transgenic mice from the N2-5(A53T) line were treated
with an acute MPTP paradigm (15 mg MPTP/kg free base X 4,
every 2 hours) at 12–14 months of age. A lower than usual dose of
MPTP was used because of increased sensitivity of aged mice to
MPTP. Again, despite the significant loss of SNpc neurons in
MPTP treated mice (ANOVA, p,0.05), no increase in
susceptibility is observed in transgenic overexpressors versus
non-transgenic cohorts (Fig. 2B).
Effect of high expression levels of A53T in mice on the
susceptibility of dopaminergic neurons to MPTP. To be
certain that overexpression of human a-synuclein does not affect
MPTP susceptibility, we also examined the MPTP susceptibility of
the A53T transgenic mice expressing very high levels of A53T
human a-synuclein. Transgenic mice from line G2-3(A53T)
express the transgene at approximately six times the level of
endogenous mouse a-synuclein and develop a fatal
neurodegenerative disease with an average life span of ,12
months [11]. To investigate if this higher level of expression had a
synergistic effect with MPTP on neuronal toxicity, 6 month old
transgenic and non-transgenic littermates were treated with acute
MPTP paradigm (18 mg MPTP/kg free base X 4, every 2 hours)
and numbers of neurons in SNpc were determined (Fig. 2C).
Analysis of cell counts show that MPTP treatment of A53T
transgenic mice (65%) may result in a slightly lower number of
a-Synuclein Dependent Regulation of b-Synuclein
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(70.4%) (Fig. 2C). Specifically, the difference in number of TH-
immunopositive neurons between the MPTP treated non-
transgenic mice and A53T transgenic mice are significant when
the ANOVA analysis performed with the Neuman-Keuls-post-test
(p,0.05). However, the differences are not significant when
ANOVA analysis with Tukey-Kramer posthoc test was applied.
Collectively, these results indicate that the increased expression of
human a-synuclein (either wild type or mutant) do not significantly
affect MPTP susceptibility and, at best, very high levels of A53T
mutant human a-synuclein is required to slightly increase the
vulnerability of dopaminergic neurons to MPTP-toxicity.
Human a-synuclein complements MPTP-resistance
phenotype but not the developmental reduction of
dopaminergic neurons in a-synuclein null mice
The lack of increased MPTP susceptibility with the human a-
synuclein transgenic mice is surprising since decreased expression
of mouse a-synuclein is associated with significant protection from
MPTP-intoxication [21,29,30,31,40]. One possibility is that
human and mouse a-synuclein function differently regarding
MPTP-susceptibility in mice.
To test the above possibility, we examined whether expression
of human a-synuclein could restore the susceptibility of dopami-
nergic neurons to MPTP toxicity in mouse a-synuclein null mice.
To test whether human a-synuclein expression can complement
the MPTP-resistant phenotype of the mouse a-synuclein null mice,
human a-synuclein transgenic mice (WT and A53T) were
successively crossed to the mouse a-synuclein null mice [41] to
generate human a-synuclein transgenic mice lacking mouse a-
synuclein expression (Fig. 3A). The resulting mice were subjected
to acute MPTP intoxication and nigrostriatal dopaminergic
neurotoxicity was studied by performing stereologic neuronal
counts of SNpc and quantitation of striatal dopamine and its
metabolites 1 week after MPTP (20 mg MPTP/kg free base X4,
every 2 hours) in 6–8 week old male mice. Consistent with
previous reports [21,28,30], the a-synuclein null mice are
protected against MPTP-induced neurodegeneration at both
striatum and SNpc (Fig. 3B, C). MPTP-induced reductions in
striatal metabolites of dopamine, DOPAC and HVA and also
increased dopamine turnover (DOPAC+HVA/DA) are blocked in
a-synuclein null mice (data not shown). However, mice expressing
human a-synuclein (wild type and A53T) on the mouse a-
synuclein null background show significant sensitivity to MPTP
Figure 1. Nigrostriatal system in transgenic wild type and mutant human a-synuclein overexpressing mice do not show increased
sensitivity to acute MPTP intoxication. Transgenic mice expressing moderate levels (,3-fold over endogenous levels) of wild type (WT, line I2-
2), A30P mutant (line T3), and A53T mutant (line N2-5) human a-synuclein were subjected to acute paradigm of MPTP (18 mg MPTP/kg free base X4,
every 2h). A. Striatal levels of dopamine and major metabolite DOPAC in transgenic and non-transgenic littermate cohorts were analyzed 7 days after
the last MPTP injection. No differences were seen among transgenic and non-transgenic mice receiving the same treatments (saline or MPTP). B.
Stereologic neuronal counts of TH-immunopositive and total neurons in transgenic and non-transgenic littermate cohorts analyzed two weeks
following the last MPTP injection. While MPTP treatments caused a significant reduction in TH-immunopositive and total neurons, no significant
differences in neuronal counts are observed between transgenic and non transgenic mice receiving the same treatment (saline or MPTP). Data
represent mean 6 SEM. *p,0.05, statistical significance versus saline controls using two way ANOVA, n=5-6 per group, n.s not significant.
doi:10.1371/journal.pone.0016706.g001
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nergic neurons following MPTP treatment in human a-synuclein/
mouse a-synuclein null mice were comparable to that seen with
the wild type animals (Fig. 3D,E). Furthermore, human a-
synuclein/mouse a-synuclein null mice were equally sensitive as
the wild type mice on the levels of dopamine metabolites following
MPTP (data not shown).
The finding that MPTP-neurotoxicity resistant phenotype of the
mouse a-synuclein null mice is completely reversed by the
expression of human a-synuclein transgenes show that the lack
of robust enhancement in MPTP neurotoxicity in human a-
synuclein transgenic mice is not because human a-synuclein can
not function in the MPTP toxicity pathway. A likely possibility is
that the level of mouse a-synuclein is saturating and the additional
a-synuclein expression does not significantly increase the effects of
a-synuclein on susceptibility to MPTP neurotoxicity.
Significantly, while the human a-synuclein can complement
mouse a-synuclein in regard to MPTP neurotoxicity, human a-
synuclein does not completely complement all of the phenotypes of
mouse a-synuclein null mice. Mouse a-synuclein null mice have
significantly fewer TH+ neurons in SNpc (Fig. 3E) due to
developmental reduction in the number of TH+ neurons
generated [31] Expression of human a-synuclein in mouse a-
synuclein null mice did not restore the number of TH+ neurons to
the level of non-transgenic mice (Fig. 3E).
Decreased vulnerability of a-synuclein null mice to
intoxication is selective for dopaminergic neurons
It’s believed that a-synuclein null mice are protected against
MPTP intoxication because lack of a-synuclein expression affects a
yet to be defined process that occurs post uptake of MPP+ into the
terminal and pre-mitochondrial complex I inhibition [42]. Based
on this hypothesis, potential factors that can be affected by the loss
of a-synuclein expression and also modulate MPTP toxicity is the
activity of the vesicular monoamine transporter 2 (VMAT2) and
the ability of MPP+ to access mitochondrial complex-I. To test
whether these factors could be involved, we examined whether the
serotoninergic and noradrenergic neurons in mouse a-synuclein
null mice were resistant to 29NH2-MPTP neurotoxicity.
Intoxication with 29NH2-MPTP leads to degeneration of
serotoninergic and noradrenergic neurons without affecting
dopaminergic neurons (Table 1 and Fig. 4A and B) [32]. The
mode of 29NH2-MPTP toxicity is virtually identical to that of
MPTP [33,43,44]. Thus, we reasoned that if a-synuclein
modulates a general synaptic trafficking of MPP+, mouse a-
synuclein null mice should be resistant to 29NH2-MPTP toxicity.
Mouse a-synuclein null and the littermate wild type mice were
generated by mating two mice that are both heterozygous for the
mouse a-synuclein gene. Six to eight week old male mice were
treated with 29NH2-MPTP (15 mg 29NH2-MPTP/kg X4, every
2 hours) and the levels of serotonin and norepinephrine in the
cortex, striatum, and brain stem were determined 14 days
following the last 29NH2-MPTP treatment. Our results show that
29NH2-MPTP treatment leads to the profound reductions in the
serotonin and norepinephrine levels in all brain regions. The
magnitudes of reductions in neurotransmitter levels were compa-
rable between wild type and a-synuclein null mice (Fig. 4A, B).
Analysis of serotoninergic innervations by immunohistochemical
analysis confirms the significant loss of cortical serotoninergic
fibers following 29NH2-MPTP treatments in both groups of mice
(Fig. 4C). Qualitatively, the losses of serotoninergic fibers were
notably greater in the a-synuclein null mice than in the wild type
controls.
The lack of resistance to the 29NH2-MPTP toxicity in the a-
synuclein null mice suggests that MPTP resistance phenotype of
mouse a-synuclein null mice is selective for dopaminergic neurons.
Further, our results suggest that alterations in the general
metabolism and/or trafficking of MPP+ in the synaptic terminal
are not involved in MPTP resistant phenotype of the mouse a-
synuclein null mice. Even if such a phenomenon does exist, it
might be due to yet undefined inherent mechanisms that differ in
dopaminergic and serotoninergic/noradrenergic neurons that
affect the general metabolism or trafficking of MPP+.
The levels of b-synuclein and phosphorylated Akt are
regulated by a-synuclein expression in ventral midbrain
Previously, increased expression of b-synuclein was found in the
mouse a-synuclein null and mouse c-synuclein null mice [31].
Because, b-synuclein has been shown to protect neurons from cell
death, potentially via regulation of p53 [45], by reducing a-
synuclein protein expression [46,47] and Akt-phosphorylation
[48,49], increased levels of b-synuclein in a-synuclein null mice
could be a potential factor involved in the protection of
dopaminergic neurons from MPTP toxicity.
To further explore this hypothesis, we examined whether the
increased levels of b-synuclein is regionally selective and whether
the increase in b-synuclein levels in a-synuclein null mice could be
reversed by expression of human a-synuclein. To determine
whether b-synuclein levels are increased in brains of a-synuclein
null mice, SDS-soluble proteins from cortex and ventral midbrain
were subjected to immunoblotting for b-synuclein (Fig. 5A).
Semi-quantitative analysis show that, relative to the b-synuclein
levels in wild type mice, the ventral midbrain, but not cortex,
shows increased levels of b-synuclein in a-synuclein null mice
(Fig. 5B). Significantly, the level of b-synuclein is returned to the
wild type levels by expressing human a-synuclein in the a-
synuclein null background. Additionally, analysis of SDS soluble
proteins in other brain regions like dorsal medial brain stem did
not significantly affect b-synuclein levels for all the genotypes in
comparison to wild type mice (data not shown).
Figure 2. Effects of sub acute MPTP regimen, aging, and transgene expression level on the MPTP sensitivity of nigral dopaminergic
neurons in human A53T a-synuclein transgenic mice. A. Stereologic cell counts of total and TH-immunopositive neurons of SNpc in non
transgenic and human A53T transgenic mice (line N2-5, ,3-fold) analyzed two weeks after a sub-acute paradigm of MPTP (30 mg MPTP/kg free base
once a day for 5 days). Although sub acute MPTP caused significant reductions in total and TH-positive neurons no significant differences were seen
among transgenic and non transgenic mice receiving the same treatments (saline or MPTP). B. TH-positive and total neuronal counts in SNpc of 12-14
month old non transgenic and human A53T transgenic mice (line N2-5) after acute MPTP (15 mg MPTP/kg free base X4, every 2 h) at 7 days. Acute
MPTP in older mice caused significant reduction in total and TH-positive neurons no significant differences were seen among transgenic and non
transgenic mice receiving the same treatments (saline or MPTP). C. Cell counts of TH-positive and total neurons in high expressing lines of human
A53T transgenic mice (G2-3 line, ,6-fold) 7 days after acute MPTP intoxication (18 mg MPTP/kg free base X4, every 2 h). MPTP-intoxication resulted
in a significant reduction of total and TH-positive neuronal counts in non transgenic and high expressing lines of A53T transgenic mice compared to
saline treatments. A moderate increase in the vulnerability was observed in A53T transgenic mice. Data represent mean 6 SEM. *p,0.05, statistical
significance versus saline controls using two way ANOVA, n=5-6 per group, n.s., not significant. #, significant using Neuman-Keuls post-test (p,0.05)
but not with the Tukey-Kramer post test.
doi:10.1371/journal.pone.0016706.g002
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16706Figure 3. Human a-synuclein complements MPTP resistant phenotype of mouse a-synuclein null mice. A. Expression of mouse and
human a-synuclein in wild type (WT), mouse a-synuclein nulls (KO) and mice expressing wild type human a-synuclein (line I2-2) on a mouse a-
synuclein null background (hWT/KO), total proteins isolated from 9 month old striata were subjected to immunoblot analysis for total a-synuclein
(Syn-1), human a-synuclein (HuSyn), and GAPDH. B and C. TH-immunostaining staining of striatum (B) and SNpc (C) 7 days following saline or acute
MPTP (20 mg/kg free base four times every 2 hour) treatment in wild type (WT), mouse a-Syn nulls (KO) and human a-Syn transgenic [wild type (hWT,
line I2-2) and A53T (line N2-5)] on the mouse a-Syn null background (hWT/KO; A53T/KO). Only the KO is protected from MPTP toxicity. D and E. MPTP
intoxication results in significant reductions in striatal DA-levels (D) and TH-positive neuronal cells (E) in mice with either mouse or human a-Syn
expression. The a-Syn KO mice were completely protected against MPTP. The reduced basal number of DAergic neurons in a-Syn KO mice was not
complemented by the human a-Syn expression (E). Data represent mean 6 SEM.
@,** p,0.05, versus saline and
# p,0.05, versus wild type MPTP,
Two way ANOVA, n=5-6, n.s not significant, scale bar: 200 mm.
doi:10.1371/journal.pone.0016706.g003
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neuroprotection via direct interaction with Akt and enhancing the
accumulation of phosphorylated Akt. Thus, we examined whether
the levels of pAkt(Ser473) was altered as a function of a-synuclein
expression in the lines of transgenic mice. Immunoblot analysis for
pAkt(Ser473) and total Akt shows that the level of pAkt(Ser473) is
increased in the ventral midbrain but not in cortex (Fig. 5A).A s
with b-synuclein expression, transgenic expression of human a-
synuclein on the a-synuclein null background lead to decrease in
pAkt(Ser473) levels (Fig 5B).
Collectively, our results support the hypothesis that the
increased expression of b-synuclein in a-synuclein null mice lead
to increased level of pAkt(Ser473), contributing to neuroprotection
in a-synuclein null mice. The finding that b-synuclein and
pAkt(Ser473) levels are selectively increased only in the ventral
midbrain of the a-synuclein null mice support our hypothesis that
dopaminergic neurons are selectively protected from MPTP-like
toxins in a-synuclein null mice.
Discussion
Both a-synuclein and MPTP are believed to cause dopaminer-
gic abnormalities that are relevant to the pathogenesis of PD, and
hence we explored the relationship between a-synuclein expres-
sion and vulnerability of dopaminergic neurons to MPTP
neurotoxicity. We show that the increased expression of human
a-synuclein is not associated with increased vulnerability of
dopaminergic neurons to MPTP toxicity. The lack of effect is
not because human a-synuclein does not function in the MPTP
toxicity pathway since human a-synuclein is able to completely
restore the MPTP-resistant phenotype of the mouse a-synuclein
null mice [21,28,29,30,31]. However, human a-synuclein does not
completely replace mouse a-synuclein since the developmental
reduction in the dopaminergic neurons is not complemented by
human a-synuclein. One plausible explanation to this could be
that the human a-synuclein might not be expressed in all cells at
similar levels and times as the endogeneous mouse a-synuclein
gene. However, we show that the lack of a-synuclein expression is
not associated with protection from the 29NH2-MPTP toxicity,
indicating that the dopaminergic neurons are selectively protected
from toxin-induced neurodegeneration in the mouse a-synuclein
null mice. Finally, a-synuclein level dependent regulation of b-
synuclein and pAkt(Ser473) expression in ventral midbrain, but not
in cortex, suggest that MPTP-resistant phenotype of a-synuclein
null mice involves neuroprotection by b-synuclein/pAkt.
Previous examinations of human a-synuclein expression and the
vulnerability to MPTP have been variable. In order to control
some of the sources of potential variation, we examined the
MPTP-sensitivity of dopaminergic neurons in human a-synuclein
transgenic mice as functions of MPTP neurotoxicity paradigms
(acute and sub-acute), human a-synuclein variants, human a-
synuclein levels, and age. Using two standard paradigms (acute
and sub acute) of MPTP neurotoxicity that results in significant
loss of dopaminergic neurons in non-transgenic controls, we
observe that wild type and mutant human a-synuclein transgenic
mice demonstrate comparable sensitivity to MPTP. However, very
high levels of A53T mutant human a-synuclein in transgenic mice
may be associated with a modest increase in the MPTP-dependent
neurodegeneration. Overall, our results are consistent with the
other reports that fail to demonstrate a synergistic effect of human
a-synuclein with MPTP [24,25]. However, one study showed that
A30P transgenic mice are more sensitive to MPTP neurotoxicity
but not to rotenone induced dopaminergic neurodegeneration
[27]. A significantly attenuated neurotoxicity in nontransgenic
mice (i.e., very little loss of dopaminergic neurons with the dose of
MPTP causing ,50% reduction in our study) observed in this
study suggest that there may be significant strain background and/
or other transgene specific effects [27]. Overall, the general lack of
increase in the vulnerability of dopaminergic neurons as a function
of increased expression of human a-synuclein suggest that even at
high levels of expression, human a-synuclein does not cause
generalized stress to dopaminergic neurons that is sufficient to
affect the MPTP toxicity paradigm used in this study. However,
we can not exclude the possibility that increased expression of
human a-synuclein would sensitize the dopaminergic neurons to
more chronic toxicity paradigms. A major difference between
MPTP-induced parkinsonism and idiopathic PD is time of
progression for symptom development, thus it is possible for acute
nature of MPTP toxicity paradigm used in this and other studies
precludes pathological interaction between a-synuclein and MPTP
toxicity [24,25]. This notion is supported by the results showing
that the expression of mutant a -synuclein is associated with the
increased vulnerability of dopaminergic neurons to chronic
application of manganese/paraquat [50].
Although, human a-synuclein and MPTP both can cause
neurodegeneration, it is plausible that these effects do not directly
interact. Arguments against this line of reasoning, however,
include findings of increased a-synuclein levels in mice SNpc
following MPTP, increased nitration of a-synuclein in mouse
SNpc following MPTP, increased a-synuclein aggregates in SNpc
of baboons following MPTP and in vitro studies of a-synuclein
toxicity [22,51,52,53]. In particular, a number of in vitro studies
show that human a-synuclein overexpression was associated with
enhanced cell death following exposure to MPP
+, the toxic
metabolite of MPTP [54,55]. Finally, studies have shown gene
dose dependent reductions in the susceptibility to MPTP in a-
synuclein null mice [21,28,29,30,31]. Given these findings, the
expectation was that increased levels of a-synuclein would
potentiate MPTP neurotoxicity. The lack of enhanced vulnera-
bility to MPTP neurotoxicity with human a-synuclein transgenic
mice raised the possibility that human a-synuclein and mouse a-
synuclein do not function equally in sensitizing dopaminergic
neurons to MPTP toxicity in vivo. However, our results show that
human a-synuclein can functionally replace mouse a-synuclein
and complements the MPTP resistant phenotype of the mouse a-
Table 1. Levels of striatal dopamine and its metabolites in
wild type and a-synuclein knock out mice following
29NH2MPTP treatment.
Treatment
groups
DA
[ng/mg]
DOPAC
[ng/mg]
HVA
[ng/mg]
DOPAC+HVA
DA
Saline
[WT]
20.362.5 1.9060.06 1.7460.04 0.1860.01
Saline
[KO]
19.461.5 1.8760.05 1.6860.05 0.1860.01
29NH2MPTP
[WT]
21.263.5 2.160.09 1.660.05 0.1760.02
29NH2MPTP
[KO]
20.564.5 1.960.08 1.7360.08 0.1760.03
Striatal levels of dopamine and its metabolites measured after 2 weeks of acute
29NH2MPTP (15 mg/kg, i.p.) administered four times every two hours in wild
type and a-synuclein knock out mice. Data are expressed as mean (n=5) 6
SEM. Statistical analysis was performed by ANOVA, revealing no significant
differences among group means. DA, dopamine; DOPAC, 3,4-dihydroxy-
phenylacetic acid; HVA, homovanillic acid, WT, wild type; KO, knock out.
doi:10.1371/journal.pone.0016706.t001
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16706Figure 4. a-synuclein null mice are not protected against noradrenergic and serotoninergic neurotoxin 29NH2-MPTP. A and B. Cortical
(A) and brainstem (B) levels of norepinephrine (NE), serotonin (5-HT) and dopamine (DA) were determined two weeks after saline or acute 29NH2-
MPTP (15 mg/kg X4, every 2 hours) treatment in wild type (WT) and a-synuclein null (KO) mice. 29NH2-MPTP treatment lead to significant loss of NE
and 5-HT but not DA in cortex and brain stem. C. 29NH2-MPTP treatment resulted in a significant loss of cortical serotonergic fibers both in wild type
and a-synuclein null mice. Unlike MPTP, the a-synuclein null mice are not resistant to the neurotoxic insult of serotonergic and nor adrenergic
neurotoxin 29NH2-MPTP. Data represent mean 6 SEM. ** p,0.05, statistical significance versus saline controls using two way ANOVA, n=6-7 per
group, n.s., not significant. Scale bar: 100 mm.
doi:10.1371/journal.pone.0016706.g004
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mouse a-synuclein expression is saturating in respect to sensitizing
the dopaminergic neurons to MPTP toxicity.
Another significant finding in our study is that serotoninergic
and noradrenergic neurons in the mouse a-synuclein null mice are
exquisitely sensitive to 29NH2-MPTP toxicity. Given that the
29NH2-MPTP toxicity is mechanistically very similar to the MPTP
toxicity, lack of resistance to 29NH2-MPTP in the a-synuclein null
mice indicate that the MPTP resistance of a-synuclein null mice is
not because of alterations in the general synaptic metabolism/
targeting of MPP+. This view is supported by the study showing
that a-synuclein null mice are resistant to other mitochondrial
toxins (malonate and 3-nitropropionic acid) that affect nigrostriatal
dopaminergic neurons [56]. In this study, it was proposed that
attenuated mitochondrial toxin induced release of dopamine in a-
synuclein null mice [28] may be an important factor in
neuroprotection from mitochondrial toxin. In addition to the
potential effects of a-synuclein on dopamine release, our results
suggest that the lack of a-synuclein leads to selective protection of
nigrostriatal dopaminergic neurons from MPTP-like toxins.
Because the expression of b-synuclein, which has been shown to
be neuroprotective [45,46,48,49], is increased in the ventral
midbrain of a-synuclein null mice (Fig. 5), it seems likely that b-
synuclein expression and subsequent activation of Akt are
important contributors to the MPTP-resistant phenotype of a-
synuclein null and c-synuclein null mice [31]. This view is
consistent with the protection of dopamine neurons from 6-
OHDA toxicity by expression of a constitutively active Akt mutant
[57]. Moreover, a/b/c-synuclein-dependent regulation of Akt may
provide a mechanistic basis for modulation of dopaminergic
neurotransmission by synuclein. Specifically, regulation of Akt
signaling modulates dopamine-mediated locomotion in mice,
including amphetamine-induced locomotion, and impaired Akt
signaling is implicated in schizophrenia [58,59]. Thus, increased
activation of Akt in a-synulcein-null mice may account for the
impaired amphetamine-induced locomotor response of a-synu-
clein-null mice [41]. Finally, since increased a-synulcein expres-
sion and decreased b-synuclein expression are associated with PD
and other a-synucleinopathies [5,60], regulation of Akt activity by
synuclein expression may be an important factor in the
pathogenesis of human a-synucleinopathies. Notably, other
familial PD-linked gene products, parkin [61], DJ-1 [62,63], and
PINK1 [64,65] are also associated with Akt signaling, supporting
an intriguing notion that alterations in Akt signaling may be a
common pathologic factor in PD.
In summary, our results are consistent with the notion that a-
synuclein expression has significant cell biological consequences
for dopaminergic neurons and some of these effects, such as
vulnerability to MPTP-like toxins and regulation of b-synuclein
expression, appear to be specific for dopaminergic neurons. In
particular, given the important implications of our finding that a-
synuclein expression regulates b-synuclein expression in nigrostri-
atal system, it will be important to further study cell biological
basis for how a-synuclein regulates b-synuclein expression.
Further, our studies provide a strong rationale for critical
examination of the mechanistic relationship between Akt activation
and MPTP toxicity. Finally, given that b-synuclein can attenuate
a-synuclein toxicity in vivo [46,47,48,49], it is attractive to propose
that regulation of endogenous b-synuclein expression and Akt
activation may be a significant factor in the transgenic animal
models of a-synucleinopathy and in human a-synucleinopathies.
Materials and Methods
Animals
All mice were housed and treated in strict accordance with the
National Institutes of Health Guide for Care and use of Laboratory
Animals. Mice were housed in a pathogen free facility, about 4-5
Figure 5. Levels of a-synuclein affects b-synuclein expression and basal Akt phosphorylation in vivo. A. Total tissue extracts from cortex
and ventral midbrain of wild type (WT), moSyn-null mice (KO), and HuSyn transgenic (line I2-2) on moSyn-KO background (KO+) were immunobloted
for endogenous b-synuclein, Akt (pSer473 and total) and GAPDH. B and C. Semi-quantitative analysis of b-synuclein (B) and pSer473-Akt levels (C).
The values are mean 6 SEM from 4 animals (*p.0.05, **p.0.01, ANOVA with Newman-Keuls post-test).
doi:10.1371/journal.pone.0016706.g005
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light/dark cycle and with food and water ad libitum. All procedures
were approved by and conformed to the guidelines of the
Institutional Animal Care Committee of Johns Hopkins Univer-
sity.
Transgenic lines of mice were generated using the MoPrP
promoter as previously described to over express human a-
synuclein (WT, line I2-2, ,3-fold increase in total a-synuclein
level), A53T mutant human a-synuclein (A53T, line N2-5 and G2-
3, ,3-fold and ,6-fold increase, respectively) and A30P mutant
human a-synuclein (A30P, line T3 and O2, ,3-fold and 10-fold
increase, respectively) [11]. Non transgenic littermate cohorts were
also generated for each of these lines to account for potential
genetic differences. The transgenic mice used were N3-N5
generation backcrossed to C57/BL6 strain.
Human a-synuclein transgenic mice lacking mouse a-synuclein
expression was generated by successive mating of human a-
synuclein transgenic mice, congenic for C57BL6 strain (N10), to
mice lacking endogenous a-synuclein [41] that were procured
from Jackson labs. To generate the cohorts for the MPTP
treatment, mice that are double heterozygous for human a-
synuclein and mouse a-synuclein were mated to mice heterozy-
gous for mouse a-synuclein. The resulting progenies contained all
of the possible genotypes. The resulting male non-transgenic (wild
type), mouse a-synuclein null, and human a-synuclein transgenic
on mouse a-synuclein null background littermates were used for
the current study.
MPTP and 29NH2-MPTP treatment in mice
Male mice were used for neurotoxic challenges induced by
dopaminergic neurotoxin MPTP and its structural analogue
29NH2-MPTP, which is a selective neurotoxin for central
serotoninergic and noradrenergic neuronal systems. Two different
MPTP paradigms were used in the present study. For the acute
paradigm, mice were administered four acute doses of MPTP
(20 mg/kg, 18 mg/kg, and 15 mg/kg free base) every two hours
four times a day and analyzed 7 days post-treatment. For sub-
acute MPTP paradigm, mice were treated with 30 mg/kg free
base MPTP daily for a total of 5 days and toxicity analyses
performed two weeks after the last MPTP injection. To assess
neurotoxicity to central serotoninergic and noradrenergic system
mice were treated with 29NH2-MPTP in an acute paradigm of
15 mg/kg 29NH2-MPTP divided into four doses separated by
2 hours and the toxicity analyses were performed two weeks later.
Control cohorts of mice received equivalent volumes of saline at
the same frequency as the respective paradigms of MPTP or
29NH2-MPTP used in the study. All systemic injections were
administered through the intraperitoneal route and the neurotox-
ins were dissolved in normal saline. All procedures involving
MPTP and 29NH2-MPTP injections in mice were performed
according to standard procedures [66].
Immunohistochemistry
Immunohistochemical analyses for tyrosine hydroxylase expres-
sion was performed using methods previously described [67] using
a rabbit anti-tyrosine hydroxylase antibody (Novus Biologicals,
Littleton, CO). Serotoninergic axons were visualized by enhanced
immunocytochemistry with an anti-serotonin antibody using an
established method [68]. Briefly, formaldehyde fixed frozen
sections were incubated with the rabbit anti-serotonin antibody
(1:12,500, Incstar, Stillwater, MN) followed by the secondary
antibody [1:1000 biotin-labeled F(ab’)2 fragment goat-anti rabbit
antibody (Jackson Immunoresearch, West Grove PA)] and
visualized by incubation in biotin-streptavidin-HRP (Vector
Laboratories, Burlingame, CA) and SigmaFast
TM DAB Peroxidase
Substrate (Sigma, St. Louis, MO). Sections were mounted on glass
slides and dehydrated in graded ethanol, followed by chloroform:
ethanol (1:1) and rehydrated. The sections were then incubated in
1.5% sliver nitrate solution for 1 h at 56uC, rinsed by running tap
water for 20 min, incubated in 0.2% gold chloride at room
temperature in dark followed by distilled water rinse for 20 min
and incubated in 5% thiosulphate for 5 min at room temperature
and washed with distilled water and dehydrated in graded ethanol,
cleared in xylene, and mounted with permount.
Stereologic Cell Counts
Stereologic methods were employed to determine an unbiased
estimate of total neurons and tyrosine hydroxylase (TH)
immunopositive and Nissl-stained neurons within SNpc. Briefly,
the SNpc of mice were processed for TH immunohistochemistry
and Nissl counter stain on every fourth midbrain section
throughout the entire extent of SNpc as described previously
[67,69]. Neurons were counted using the optical fractionator [70]
using a computer-assisted image analysis system, consisting of an
Axiophot photomicroscope (Carl Zeiss Vision, Hallbergmoos,
Germany) comprising of a Zeiss planapochromat 100 X oil
objective equipped with a computer-controlled motorized stage, a
video camera, and the Stereo Investigator software (MicroBright-
Field, Williston, VT). Cell counts were performed throughout the
entire extent of the SNpc using a standard mouse [71] atlas as
anatomical reference. The total number of TH- positive neurons
was calculated using the formula previously described for this
method [72].
Measurement of biogenic amines by HPLC with
electrochemical detection
To determine the concentration of biogenic amines in discrete
brain regions by HPLC with electrochemical detection, mice were
sacrificed by decapitation and the brain was quickly removed and
discrete brain regions dissected and immediately frozen and stored
at -80uC. The tissue was weighed and sonicated in 0.2 ml of 0.1 M
perchloric acid containing 0.01% EDTA and 25 mg/ml 3,
4-dihydroxybenzylamine (DHBA) (Sigma, St. Louis, MO) as an
internal standard. After centrifugation (15,0006g, 10 min, 4uC),
20 ml of the supernatant were injected onto a C-18 reverse phase
Spheri 5, RP-18, 4.6 mm 625 cm catecholamine column (BASi,
West Lafayette, IN). The mobile phase consisted of 0.15 M
chloroacetic acid, 0.2 mM EDTA, 0.86 mM sodium octyl
sulphate, 4% acetonitrile and 2.5% tetrahydrofuran (pH=3).
The flow rate was kept at 1.5 ml/min. Biogenic amines and their
metabolites were detected by an electrochemical detector, Prostar
ECD Model 370 (Varian, Palo Alto, CA), with the working
electrode kept at 0.6 V. Data were collected and processed on a
Star Chromatography Workstation 5.52 (Varian) [67].
Immunoblot Analysis
Immunoblot analysis for synuclein and other proteins were
determined as previously described [11,73]. For the immunoblot
analysis of Akt, same procedure was used except tissue was
homogenized in the TNE buffer [10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 5 mM EDTA] containing protease inhibitors
(5 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml
pepstatin), detergent (0.5% Nonidet P-40, 0.5% Na-Deoxycholate
and 1% SDS), and a phosphatase inhibitor cocktail (Sigma).
Briefly, homogenates containing equal amount of protein were
separated by SDS-PAGE, electroblotted onto a nitrocellulose
membrane (BioRad, Hercules, CA), and immunoreacted with an
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secondary antibodies (Kirkegaard Perry Labs Inc. MD, USA). The
immunoreactive proteins were visualized by incubating the blots in
the chemiluminescence substrate (Pierce, Rockford, IL) and
detection with ChemiDoc XRS system (Biorad, Hercules, CA).
The quantitative analyses of the immunoreactive proteins were
performed with the Quantity One 1-D Analysis software (Biorad,
Hercules, CA). Statistical analysis was performed using the ratios
of the densitometric value of each band and its corresponding
GAPDH loading control within each genotype group.
To detect various synuclein variants, following primary
antibodies were used: total a-synulcein (Syn-1 mAb, BD
Biosciences Pharmingen, San Jose, CA, 1:2000); human a-
synuclein (HuSyn-1 rabbit pAb, 1:2000) [11]; b-synuclein (mAb,
Research Diagnostic Inc. Concord, MA 1:500). To detect Akt and
phosphorylated Akt levels, following primary antibodies were used:
total Akt (pAb), pAkt-Ser473 and (Cell Signalling Technology Inc.
Danvers, MA) and for loading control GAPDH (Research
Diagnostics Inc. Concord, MA, 1:5000) was used.
Statistical Analysis
Data represent mean 6 SEM from groups of animals and
statistical analysis applied with two-way ANOVA. When F values
implied significance at a level p,0.05, Fisher’s post-hoc analysis or
Tukey-Kramer multiple comparison tests was applied to deter-
mine where the differences among groups arose. All statistical
analyses were performed using the Prism software (GraphPad, San
Diego, CA).
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